[
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) is “the Great Drug Company on Earth,” Says Jim Cramer",
    "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Eli Lilly and Company (NYSE:LLY) is one of the stocks on Jim Cramer’s radar. Healthcare giant Eli Lilly and Company (NYSE:LLY) is one of Cramer’s top stocks in the sector. Throughout 2025, the CNBC TV host praised the company, not only for its weight loss drug […]",
    "url": "https://finnhub.io/api/news?id=8d1635e80eff13bbb246b78208be398fda0d1fbf65f60aced02738a1b92f1060",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770575516,
      "headline": "Eli Lilly (LLY) is “the Great Drug Company on Earth,” Says Jim Cramer",
      "id": 138395444,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Eli Lilly and Company (NYSE:LLY) is one of the stocks on Jim Cramer’s radar. Healthcare giant Eli Lilly and Company (NYSE:LLY) is one of Cramer’s top stocks in the sector. Throughout 2025, the CNBC TV host praised the company, not only for its weight loss drug […]",
      "url": "https://finnhub.io/api/news?id=8d1635e80eff13bbb246b78208be398fda0d1fbf65f60aced02738a1b92f1060"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Shares Surge on Weight-Loss Drug Momentum. Is It Time to Buy the Stock?",
    "summary": "It doesn't look too late to buy the stock.",
    "url": "https://finnhub.io/api/news?id=9485b01a16e2d2f7d7935ce6cd82e3ec38ad1079cf3bce7c1fa36c237354b53f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770567900,
      "headline": "Eli Lilly Shares Surge on Weight-Loss Drug Momentum. Is It Time to Buy the Stock?",
      "id": 138394379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "It doesn't look too late to buy the stock.",
      "url": "https://finnhub.io/api/news?id=9485b01a16e2d2f7d7935ce6cd82e3ec38ad1079cf3bce7c1fa36c237354b53f"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk A/S (NVO) Eyes Solidifying Its Market Position with Increased Advertising Spending",
    "summary": "Novo Nordisk A/S (NYSE:NVO) is included in our list of the 13 Best Extremely Profitable Stocks to Invest in Now. According to a January 28, 2026, Reuters report, Novo Nordisk A/S (NYSE:NVO) increased its advertising spending for its GLP-1 medication in the U.S. In the first nine months of 2025, the company allocated nearly $500 million to […]",
    "url": "https://finnhub.io/api/news?id=d1b2a4bf04c28e532e9953fbb3a0cf9ba7cdfbe780555d8c64dcaf040119359c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770564426,
      "headline": "Novo Nordisk A/S (NVO) Eyes Solidifying Its Market Position with Increased Advertising Spending",
      "id": 138393575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk A/S (NYSE:NVO) is included in our list of the 13 Best Extremely Profitable Stocks to Invest in Now. According to a January 28, 2026, Reuters report, Novo Nordisk A/S (NYSE:NVO) increased its advertising spending for its GLP-1 medication in the U.S. In the first nine months of 2025, the company allocated nearly $500 million to […]",
      "url": "https://finnhub.io/api/news?id=d1b2a4bf04c28e532e9953fbb3a0cf9ba7cdfbe780555d8c64dcaf040119359c"
    }
  },
  {
    "ts": null,
    "headline": "Analysts Project Eli Lilly (LLY) to Deliver 21%+ Revenue Growth and 40%+ Adjusted Earnings Growth in 2026",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Extremely Profitable Stocks to Invest in Now. On February 2, 2026, Reuters reported that long-standing expectations that the global obesity drug market would reach $150 billion over the next decade are being reconsidered amid declining U.S. prices for GLP-1 therapies and intensifying competition. The new projections […]",
    "url": "https://finnhub.io/api/news?id=0cbd75a356c3a20583b51e08eb23156ebd416e21e2772244dbb31823e1cbe8e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770564418,
      "headline": "Analysts Project Eli Lilly (LLY) to Deliver 21%+ Revenue Growth and 40%+ Adjusted Earnings Growth in 2026",
      "id": 138393576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Extremely Profitable Stocks to Invest in Now. On February 2, 2026, Reuters reported that long-standing expectations that the global obesity drug market would reach $150 billion over the next decade are being reconsidered amid declining U.S. prices for GLP-1 therapies and intensifying competition. The new projections […]",
      "url": "https://finnhub.io/api/news?id=0cbd75a356c3a20583b51e08eb23156ebd416e21e2772244dbb31823e1cbe8e8"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Ties TrumpRx Pricing To GLP-1 Growth And New Therapies",
    "summary": "Eli Lilly (NYSE:LLY) has joined the Trump administration’s TrumpRx program to provide discounted pricing on select high demand therapies in the U.S. The company announced new collaborations focused on autoimmune diseases and hearing loss, targeting large patient populations with unmet medical needs. Lilly is moving ahead with multibillion dollar U.S. manufacturing expansion, including an advanced facility in Pennsylvania, to support next generation medicines. Eli Lilly sits at the center of...",
    "url": "https://finnhub.io/api/news?id=a87c770126030cce2a62fe2db62948998f2e756b59dba68654dde175de9af524",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770552512,
      "headline": "Eli Lilly Ties TrumpRx Pricing To GLP-1 Growth And New Therapies",
      "id": 138392889,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) has joined the Trump administration’s TrumpRx program to provide discounted pricing on select high demand therapies in the U.S. The company announced new collaborations focused on autoimmune diseases and hearing loss, targeting large patient populations with unmet medical needs. Lilly is moving ahead with multibillion dollar U.S. manufacturing expansion, including an advanced facility in Pennsylvania, to support next generation medicines. Eli Lilly sits at the center of...",
      "url": "https://finnhub.io/api/news?id=a87c770126030cce2a62fe2db62948998f2e756b59dba68654dde175de9af524"
    }
  },
  {
    "ts": null,
    "headline": "Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology",
    "summary": "Innovent Biologics, Inc. (\"Innovent\") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, today announced a strategic collaboration with Eli Lilly and Company (\"Lilly\") to advance novel medicines in oncology and immunology. This agreement marks the seventh collaboration between the two companies, deepening a",
    "url": "https://finnhub.io/api/news?id=18fbd0394fb763d3dbf8237395bc80f70347da0e0794d6911176aed6690befe4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770545100,
      "headline": "Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology",
      "id": 138392165,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Innovent Biologics, Inc. (\"Innovent\") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, today announced a strategic collaboration with Eli Lilly and Company (\"Lilly\") to advance novel medicines in oncology and immunology. This agreement marks the seventh collaboration between the two companies, deepening a",
      "url": "https://finnhub.io/api/news?id=18fbd0394fb763d3dbf8237395bc80f70347da0e0794d6911176aed6690befe4"
    }
  },
  {
    "ts": null,
    "headline": "Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.",
    "summary": "Eli Lilly is the leader in the GLP-1 space, but here's another GLP-1 stock and a medical device maker to consider.",
    "url": "https://finnhub.io/api/news?id=2f46f3b2854fc47759df7bd2274d524fe3d2179a49341251ecd7ea42da192791",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770519000,
      "headline": "Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.",
      "id": 138390234,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly is the leader in the GLP-1 space, but here's another GLP-1 stock and a medical device maker to consider.",
      "url": "https://finnhub.io/api/news?id=2f46f3b2854fc47759df7bd2274d524fe3d2179a49341251ecd7ea42da192791"
    }
  }
]